Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious condition that can occur after a SARS-CoV-2 infection, commonly known as COVID-19. It involves fever, organ dysfunction, and increased inflammation markers. It was initially described as a post- infection complication of SARS-CoV-2 virus. With the development of vaccines and the efforts to control the spread of the virus, the incidence of MIS-C has decreased. There is no specific test to diagnosis a patient with this condition For patients with symptoms of MIS-C, clinicians perform a thorough evaluation, which may include blood tests, scans etc. Patients are also tested for the presence of antibodies to SARS-CoV2, the virus that causes COVID-19. When it comes to the treatment of Multisystem Inflammatory Syndrome in Children (MIS-C), it typically involves a multidisciplinary approach and may vary depending on the severity of the condition. Treatment often includes hospitalization for close monitoring and supportive care. This can involve intravenous fluids, medications to reduce inflammation, and management of specific organ complications. In some cases, additional interventions such as immunoglobulin therapy or steroids may be used.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: World Journal of Biology Pharmacy and Health Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
